| First Author | Tian T | Year | 2020 |
| Journal | Cancer Immunol Res | Volume | 8 |
| Issue | 5 | Pages | 660-671 |
| PubMed ID | 32161110 | Mgi Jnum | J:300586 |
| Mgi Id | MGI:6502922 | Doi | 10.1158/2326-6066.CIR-19-0552 |
| Citation | Tian T, et al. (2020) IL1alpha Antagonizes IL1beta and Promotes Adaptive Immune Rejection of Malignant Tumors. Cancer Immunol Res 8(5):660-671 |
| abstractText | We assessed the contribution of IL1 signaling molecules to malignant tumor growth using IL1beta(-/-), IL1alpha(-/-), and IL1R1(-/-) mice. Tumors grew progressively in IL1R(-/-) and IL1alpha(-/-) mice but were often absent in IL1beta(-/-) mice. This was observed whether tumors were implanted intradermally or injected intravenously and was true across multiple distinct tumor lineages. Antibodies to IL1beta prevented tumor growth in wild-type (WT) mice but not in IL1R1(-/-) or IL1alpha(-/-) mice. Antibodies to IL1alpha promoted tumor growth in IL1beta(-/-) mice and reversed the tumor-suppressive effect of anti-IL1beta in WT mice. Depletion of CD8(+) T cells and blockade of lymphocyte mobilization abrogated the IL1beta(-/-) tumor suppressive effect, as did crossing IL1beta(-/-) mice to SCID or Rag1(-/-) mice. Finally, blockade of IL1beta synergized with blockade of PD-1 to inhibit tumor growth in WT mice. These results suggest that IL1beta promotes tumor growth, whereas IL1alpha inhibits tumor growth by enhancing T-cell-mediated antitumor immunity. |
